It’s only fair to share… Vepdegestrant CAS 2229711-08-2 MW 723.9 g/mol, C45H49N5O4 (3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenyl]piperidin-4-yl]methyl]piperazin-1-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione 5/1/2026, FDA 2026, APROVALS 2026, Veppanu, ARV 471, WC1U3R1YMI, PF 07850327 To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy On May 1, 2026, the …
Tag «ANAX LAB»
Dencatistat
It’s only fair to share… Dencatistat CAS 2377000-84-3 MFC24H27N7O5S MW 525.6 g/mol 4-[2-(cyclopropylsulfonylamino)pyrimidin-4-yl]-N-[5-(6-ethoxypyrazin-2-yl)-2-pyridinyl]oxane-4-carboxamide 4-[2-(cyclopropanesulfonamido)pyrimidin-4-yl]-N-[5-(6-ethoxypyrazin-2-yl)pyridin-2-yl]oxane-4-carboxamideCTP synthase 1 inhibitor, antineoplastic, STP 938, CTPS1-IN-2, QG9C9SZZ3T Dencatistat (formerly known as STP938) is a first-in-class, orally bioavailable cancer drug designed to target specific blood cancers and solid tumours Dencatistat is an orally bioavailable, small molecule inhibitor of cytidine triphosphate synthase 1 (CTPS1), with …
Delocamten
It’s only fair to share… Delocamten CAS 2417411-02-8 MFC19H21F2N3O3 MW377.4 g/mol Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, 6-fluoro-7-(2-fluoro-5-methylphenyl)-5,6,7,8-tetrahydro-3-(tetrahydro-2H-pyran-4-yl)-, (6S,7S)- (6S,7S)-6-fluoro-7-(2-fluoro-5-methylphenyl)-3-(oxan-4-yl)-5,6,7,8-tetrahydro-1H-pyrido[2,3-d]pyrimidine-2,4-dione (6S,7S)-6-fluoro-7-(2-fluoro-5-methylphenyl)-3-(oxan-4-yl)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dionecardiac myosin inhibitor, MYK-224; BMS-986435, MYK 224, BMS 986435, IE5886BN8T Delocamten (development code MYK-224) is a small-molecule cardiac myosin inhibitor developed by Bristol Myers Squibb for hypertrophic cardiomyopathy.[1][2][3] Delocamten is a small molecule drug. Delocamten is under investigation in clinical trial NCT06122779 (Study to Evaluate Safety, Tolerability and …
Darlifarnib
It’s only fair to share… Darlifarnib CAS 2939824-30-1 MF C29H20N6O MW 468.51 14-amino-14-(3-methylimidazol-4-yl)-7-oxa-19-azapentacyclo[13.6.2.12,6.19,13.018,22]pentacosa-1(22),2(25),3,5,9,11,13(24),15(23),16,18,20-undecaene-10,20-dicarbonitrile farnesyl transferase inhibitor, antineoplastic, KO-2806, KO 2806, T206317 Darlifarnib (KO-2806) is an investigational, orally active next-generation farnesyl transferase inhibitor (FTI) being developed by Kura Oncology to treat solid tumors, such as clear cell renal cell carcinoma (ccRCC). It inhibits the enzyme farnesyl transferase, blocking KRAS and …
Danifexor
It’s only fair to share… Danifexor CAS 2648738-68-3 MF C29H20Cl2N2O5 MW547.386 6-[6-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]naphthalen-2-yl]oxypyridine-3-carboxylic acid 3-Pyridinecarboxylic acid, 6-[[6-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl]methoxy]-2-naphthalenyl]oxy]- farnesoid X receptor agonist, TUU8G1CX9O, HEC 96719, ASC42 Danifexor is an investigational drug that acts as a potent and selective agonist for the farnesoid X receptor (FXR). It was primarily being developed for the treatment of liver diseases such as …
Dabogratinib
It’s only fair to share… Dabogratinib CAS 2800223-30-5 MF C25H24Cl2N6O3S, 559.5 g/mol 5-[(1R)-1-(3,5-dichloro-4-pyridinyl)ethoxy]-3-[6-(2-methylsulfonyl-2,6-diazaspiro[3.3]heptan-6-yl)-3-pyridinyl]-1H-indazole (R)-5-(1-(3,5-Dichloropyridin-4-yl)ethoxy)-3-(6-(6-(methylsulfonyl)-2,6-diazaspiro[3.3]heptan-2-yl)pyridin-3-yl)-1H-indazole [6-(5-{5-[(1R)-1-(3,5-dichloropyridin-4-yl)ethoxy]-1H-indazol-3-yl}pyridin-2-yl)-2,6-diazaspiro[3.3]heptan-2-yl](methyl)-λ6sulfanedioneTYRA-300fibroblast growth factor receptor inhibitor, antineoplastic, TYRA-300, TYRA 300, A1AV2, FH245S2JZJ Dabogratinib (TYRA-300) is an orally active, highly selective inhibitor of fibroblast growth factor receptor 3 (FGFR3), designed to treat cancers with FGFR3 alterations and genetic diseases like achondroplasia. It shows potent tumor …
Colfosceril miristate
It’s only fair to share… Colfosceril miristate CAS 18194-24-6 MF C36H72NO8P MW677.9325 1,2 Dimyristoyl glycero 3 phosphorylcholine (2R)-2,3-bis(tetradecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphatesurfactant replacement, DIMYRISTOYL LECITHIN, Dimyristoyllecithin, DMCP, DMPC Colfosceril miristate (1,2-dimyristoyl-sn-glycero-3-phosphocholine or DMPC) is a synthetic phospholipid commonly used in research to study lipid bilayers, liposomes, and drug delivery systems. It serves as a model membrane system due …
Anvumetostat
It’s only fair to share… Anvumetostat CAS 2790567-82-5 MF C22H19F3N4O3 MW444.4 g/mol (4-amino-1,3-dihydrofuro[3,4-c][1,7]naphthyridin-8-yl)-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]methanone (4-amino-1,3-dihydrofuro[3,4-c][1,7]naphthyridin-8-yl){(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl}methanoneantineoplastic, AMG 193, QAT649EJ5E, PRMT5-IN-27, Anvumetostat (also known as AMG 193) is an orally available, small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), primarily being developed for the treatment of advanced solid tumours with MTAP-null (methylthioadenosine phosphorylase-deficient) mutations. Mechanism of Action Clinical Development Anvumetostat was initially developed by Amgen, …
Amsulostat
It’s only fair to share… Amsulostat CAS 2409963-83-1 MF C13H13FN2O2S MW280.32 2-Buten-1-amine, 3-fluoro-4-(8-quinolinylsulfonyl)-, (2Z)- (2Z)-3-fluoro-4-(quinolin-8-ylsulfonyl)but-2-en-1-amine (Z)-3-fluoro-4-quinolin-8-ylsulfonylbut-2-en-1-amine (2Z)-3-fluoro-4-(quinolin-8-ylsulfonyl)but-2-en-1-amineprotein-lysine-oxidase (LOX) inhibitor, antifibrotic, PXS 5505, LOX inhibitor PXS-5505, LOX-IN-3, pan-LOX inhibitor PXS-5505, DO94E28WYW, SNT 5505 Amsulostat is an orally available, small-molecule, irreversible inhibitor of all lysyl oxidases (LOX) family members, with potential antifibrotic activity. Upon oral administration, amsulostat …
Amezalpat
It’s only fair to share… Amezalpat CAS 1616372-41-8 MF C34H41N3O4 MW555.7 g/mol 2-[5-[3-[3-[1-[(4-tert-butylphenyl)methyl]-4-ethyl-5-oxo-1,2,4-triazol-3-yl]propyl]phenyl]-2-ethoxyphenyl]acetic acid peroxisome proliferator-activated receptor alpha (PPARα) antagonist, antineoplastic, TPST 1120, FDA Fast Track, Orphan Drug, 1EQ4LQN9N3 Amezalpat (formerly TPST-1120) is an investigational, oral, small-molecule inhibitor targeting peroxisome proliferator-activated receptor alpha (PPAR being developed by Tempest Therapeutics. It works by directly targeting tumor cells and reducing immune …